Merck & Co., Inc. (MRK)
Exploring Analyst Estimates for Merck (MRK) Q2 Earnings, Beyond Revenue and EPS
Beyond analysts' top-and-bottom-line estimates for Merck (MRK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Will Keytruda Continue to Aid MRK's Top Line Ahead of Q2 Earnings?
Merck's Keytruda drives nearly half of its pharma sales. Investors eye Q2 momentum amid existing competition.
Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rapid Micro Biosystems: Benefiting From Partnership With Merck; Initiating With 'Buy'
Initiating Rapid Micro Biosystems at 'buy' with $4.60 fair value, driven by strong growth potential in automated microbial quality control market. Growth Direct platform offers clear advantages over manual MQC, with automation, regulatory benefits, and a $10B addressable market opportunity. Merck partnership is a key catalyst, enabling global distribution, supply chain optimization, and improved gross margins for Rapid Micro Biosystems.
Merck (MRK) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Merck (MRK) stood at $79.96, denoting a -1.91% move from the preceding trading day.
Merck & Co., Inc. (MRK) Presents at HIV Investor Event Transcript
Merck & Co., Inc. (NYSE:MRK ) HIV Investor Event July 17, 2025 9:00 AM ET Company Participants Chirfi Guindo - Senior VP & Chief Marketing Officer of Human Health Eliav Barr - Chief Medical Officer & Head of Global Clinical Development of Merck Research Laboratories Elizabeth Rhee - Corporate Participant Kathryn Hayward - Corporate Participant Peter Dannenbaum - Vice President of Investor Relations Conference Call Participants Alexandria Janet Hammond - Wolfe Research, LLC Asad Haider - Goldman Sachs Group, Inc., Research Division Courtney Breen - Sanford C. Bernstein & Co., LLC.
Why Merck Is A Better Dividend Stock Than Gilead Sciences
I reiterate my Hold rating on Merck & Co., Inc. and downgrade Gilead Sciences, Inc. to Sell, as MRK outperforms on dividend growth and valuation metrics. Compared to GILD, MRK features a longer dividend growth streak, a higher recent dividend increase, and a superior PEGY ratio. Both companies have similar payout ratios and mixed buyback histories, but GILD's inventory management is notably better than MRK's.
Brokers Suggest Investing in Merck (MRK): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Merck (MRK) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Merck (MRK) stood at $81.52, denoting a -2.57% move from the preceding trading day.
Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention
MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.
MRK's Buyout Spree to Broaden Product Portfolio: Can it Aid Growth?
Merck's impending Verona buyout and recent biotech deals aim to expand its pipeline and cut reliance on Keytruda sales.
